BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report) was up 1.6% on Monday . The company traded as high as C$4.58 and last traded at C$4.42. 5,970 shares traded hands during mid-day trading, a decline of 72% from the average daily volume of 20,989 shares. The stock had previously closed at C$4.35.
BriaCell Therapeutics Price Performance
The stock’s 50-day moving average price is C$4.80 and its 200-day moving average price is C$6.38. The company has a market capitalization of C$40.37 million, a price-to-earnings ratio of -5.52 and a beta of 2.06.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to developing novel immunotherapies to fight cancer and improve patients’ lives. Immunotherapies have become the forefront of the fight against cancer because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy, and may also prevent cancer recurrence.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
